Wind-down of stem-cell institute leaves a void
By Jeanne F. Loring,
Nature
| 08. 07. 2019
For the past dozen or so years, stem-cell researchers in California have been the envy of the world. In 2004, as a rebuke to the restrictions put in place in the United States by then-president George W. Bush on funding for human embryonic stem-cell research, Californians approved US$3 billion in taxpayer funds to support regenerative medicine. That essentially guaranteed that the state would become the centre of innovation in the field.
Since then, almost all of my research funding has come from the California Institute for Regenerative Medicine (CIRM). But not for much longer.
In June, CIRM announced that it was no longer accepting new grant applications. Its money is running out, leaving researchers with fewer resources to develop stem-cell-based therapies. That same month, several of us stem-cell scientists were featured in a documentary series that promoted unproven stem-cell treatments and was partially funded by a for-profit clinic facing federal charges. We learnt about the nature of the series after that clinic sent mass e-mails promoting it. The film-makers removed interview footage at our request.
This coincidence demonstrates the double-edged...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...